{"pageContent": "Purpose: Feasibility of targeted and volumetric hyperthermia (40-45 \u00b0C) delivery to the prostate with a commercial MR-guided endorectal ultrasound phased array system, designed specifically for thermal ablation and approved for ablation trials (ExAblate 2100, Insightec Ltd.), was assessed through computer simulations and tissue-equivalent phantom experiments with the intention of fast clinical translation for targeted hyperthermia in conjunction with radiotherapy and chemotherapy.", "metaData": {"source": "[First-line therapy for \"high-risk prostate cancer\". HELP - high intensity focused ultrasound (HIFU) and Eilgard in patients with high-risk prostate cancer - a prospective, randomized study (AP 62/10 of the AUO)]\nhttps://pubmed.ncbi.nlm.nih.gov/24939285/"}}